Clinical trials: Attention Deficit Disorder
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
ADHD, Sleep
Sleep IntervEntion as Symptom Treatment for ADHD
Up to 72% of adolescents with ADHD portray sleep problems. The most common sleep difficulties in adolescents with ADHD are initial insomnia, nocturnal awakenings, non-restorative or restless sleep.
- Conditions
- ADHD, Sleep, Adolescents, CBT
- Trial name
- SIESTA (NCT04723719)
- Testing
- SIESTA, Treatment as usual for ADHD
- Where
- Belgium
- Volunteers
- 92 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Conduct Disorder, Child
Virtual Reality to Improve Social Perspective Taking
This project will examine how virtual reality treatment that provides users with the alternate perspective of a virtual interpersonal interaction impacts psychological and neurobiological markers of social perspective taking in…
- Conditions
- Conduct Disorder, Child, Adolescent, Attention Deficit and Disruptive Behavior Disorders
- Trial name
- NCT03927612
- Testing
- Virtual reality perspective taking training, Virtual reality control perspective
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Indiana University
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
ADHD
Lifestyle Enhancement for ADHD Program
The purpose of this study is to investigate if physical activity (PA) can increase in children with Attention Deficit/Hyperactivity Disorder (ADHD) using a modified behavioral management training (BMT) program.
- Trial name
- LEAP (NCT03690674)
- Testing
- Lifestyle Enhancement for ADHD Program
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Attention Deficit Hyperactivity Disorder
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in…
- Trial name
- NCT00723190
- Testing
- CLONICEL (Clonidine HCl sustained release)
- Where
- 27 sites in United States
- Volunteers
- 303 people
- Sponsor
- Shionogi
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention Deficit-Hyperactivity
Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and…
- Trial name
- MYDAYIS (NCT03945175)
- Testing
- MYDAYIS
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
ADD, ADHD
Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein
Multicenter, Prospective, randomized, comparative and controlled study about the beneficial effects in behavior and brain connectivity of different dietary patterns in 100 children with ADHD between 7 and 12 years, followed up…
- Trial name
- BrainProtein (NCT01856686)
- Testing
- BP22042013, Low carbohydrate diet
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at 6.25 milligram (mg) in children aged 4 to 12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03325894
- Testing
- SHP465
- Where
- 48 sites in United States
- Volunteers
- 141 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit/Hyperactivity Disorder
The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
This is a single-blind, Investigator Initiated study to evaluate the safety and efficacy of Vyvanse™ and provide pilot data in two areas: (1) on the use of Near-Infrared Spectroscopy to detect medication effects in children with…
- Trial name
- VBHR (NCT00733356)
- Testing
- Vyvanse
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Kimberley Lakes
ADHD
Atomoxetine PBPK-PD Clinical Study
The primary aims of this study focus on characterizing the relationship between atomoxetine exposure and clinical outcomes, as assessed by standardized measures.
- Trial name
- NCT03154359
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Children's Mercy Hospital Kansas City
Traumatic Brain Injury, Attention Deficit Disorder
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help with attention deficits due to traumatic brain injury (TBI).
- Trial name
- NCT01000064
- Testing
- Vyvanse, fMRI
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)
Patients on chronic stimulant therapy for the treatment of Attention deficit hyperactivity disorder (ADHD) who are undergoing an outpatient surgical or diagnostic procedure will be randomized to one of two groups: stimulant…
- Trial name
- NCT01740206
- Testing
- Amphetamine and/or methylphenidate, Hold stimulant medication
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire